Mongkolpathumrat Podsawee, Pikwong Faprathan, Phutiyothin Chayanisa, Srisopar Onnicha, Chouyratchakarn Wannapat, Unnajak Sasimanas, Nernpermpisooth Nitirut, Kumphune Sarawut
Cardiovascular and Thoracic Technology Program, Chulabhorn International College of Medicine (CICM), Thammasat University (Rangsit Center), Pathumthani 12120, Thailand.
Biomedical Engineering and Innovation Research Center, Chiang Mai University, Mueang Chiang Mai District, Chiang Mai, 50200 Thailand.
Heliyon. 2024 Jan 17;10(2):e24550. doi: 10.1016/j.heliyon.2024.e24550. eCollection 2024 Jan 30.
Non-communicable diseases (NCDs) are a worldwide health issue because of their prevalence, negative impacts on human welfare, and economic costs. Protease enzymes play important roles in viral and NCD diseases. Slowing disease progression by inhibiting proteases using small-molecule inhibitors or endogenous inhibitory peptides appears to be crucial. Secretory leukocyte protease inhibitor (SLPI), an inflammatory serine protease inhibitor, maintains protease/antiprotease balance. SLPI is produced by host defense effector cells during inflammation to prevent proteolytic enzyme-induced tissue damage. The etiology of noncommunicable illnesses is linked to SLPI's immunomodulatory and tissue regeneration roles. Disease phases are associated with SLPI levels and activity changes in regional tissue and circulation. SLPI has been extensively evaluated in inflammation, but rarely in NCDs. Unfortunately, the thorough evaluation of SLPI's pathophysiological functions in NCDs in multiple research models has not been published elsewhere. In this review, data from PubMed from 2014 to 2023 was collected, analysed, and categorized into , , and clinical studies. According to the review, serine protease inhibitor (SLPI) activity control is linked to non-communicable diseases (NCDs) and other illnesses. Overexpression of the SLPI gene and protein may be a viable diagnostic and therapeutic target for non-communicable diseases (NCDs). SLPI is also cytoprotective, making it a unique treatment. These findings suggest that future research should focus on these pathways using advanced methods, reliable biomarkers, and therapy approaches to assess susceptibility and illness progression. Implications from this review will help pave the way for a new therapeutic target and diagnosis marker for non-communicable diseases.
非传染性疾病（NCDs）因其高发性、对人类福祉的负面影响以及经济成本，已成为一个全球性的健康问题。蛋白酶在病毒性疾病和非传染性疾病中发挥着重要作用。使用小分子抑制剂或内源性抑制肽抑制蛋白酶来减缓疾病进展似乎至关重要。分泌型白细胞蛋白酶抑制剂（SLPI）是一种炎症性丝氨酸蛋白酶抑制剂，可维持蛋白酶/抗蛋白酶平衡。SLPI由宿主防御效应细胞在炎症期间产生，以防止蛋白水解酶诱导的组织损伤。非传染性疾病的病因与SLPI的免疫调节和组织再生作用有关。疾病阶段与区域组织和循环中SLPI水平及活性变化相关。SLPI在炎症方面已得到广泛评估，但在非传染性疾病方面的评估较少。遗憾的是，尚未有其他地方发表过在多个研究模型中对SLPI在非传染性疾病中的病理生理功能进行的全面评估。在本综述中，收集、分析了2014年至2023年来自PubMed的数据，并将其分类为基础研究、临床前研究和临床研究。根据该综述，丝氨酸蛋白酶抑制剂（SLPI）活性控制与非传染性疾病（NCDs）及其他疾病有关。SLPI基因和蛋白的过表达可能是治疗非传染性疾病（NCDs）的一个可行的诊断和治疗靶点。SLPI还具有细胞保护作用，使其成为一种独特的治疗方法。这些发现表明，未来的研究应使用先进的方法、可靠的生物标志物和治疗方法，聚焦于这些途径，以评估易感性和疾病进展。本综述的意义将有助于为非传染性疾病的新治疗靶点和诊断标志物铺平道路。
